# Fludarabine Combined With Either Alemtuzumab or Rituximab in Treating Patients With Refractory or Relapsed B-Cell Chronic Lymphocytic Leukemia

> **NCT00086775** · PHASE2 · COMPLETED · sponsor: **Bayer**

## Conditions studied

- Leukemia

## Interventions

- **BIOLOGICAL:** alemtuzumab
- **BIOLOGICAL:** rituximab
- **DRUG:** fludarabine phosphate

## Key facts

- **NCT ID:** NCT00086775
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-07
- **Primary completion:** 2005-06
- **Final completion:** 2009-10
- **Target enrollment:** — (—)
- **Last updated:** 2013-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00086775

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00086775, "Fludarabine Combined With Either Alemtuzumab or Rituximab in Treating Patients With Refractory or Relapsed B-Cell Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00086775. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*